Table 2.
Effect of UMMS-4 on reversing ABCB1- mediated MDR in transfected cell lines
| Compounds | IC50±SD (μM) (fold-reversal) | |||
|---|---|---|---|---|
|
| ||||
| HEK293/pcDNA3.1 | HEK293/ABCB1 | |||
| Doxorubicin | 0.05916±0.0084 | (1.00) | 2.2052±0.2501 | (1.00) |
| +5 μM UMMS-4 | 0.0490±0.0069 | (1.20) | 1.3077±0.0492** | (1.68) |
| +10 μM UMMS-4 | 0.0542±0.0053 | (1.09) | 0.5115±0.0306** | (4.31) |
| +20 μM UMMS-4 | 0.0486±0.0031 | (1.21) | 0.2415±0.0087** | (9.13) |
| +10 μM Verapamil | 0.0545±0.008 | (1.08) | 0.1242±0.0249** | (17.69) |
| Cisplatin | 4.3149±0.1850 | (1.00) | 6.4096±0.2586 | (1.00) |
| +20 μM UMMS-4 | 6.1039±0.3488 | (0.71) | 6.3202±0.3918 | (1.01) |
| +10 μM Verapamil | 2.9149±0.1246 | (1.47) | 6.0898±0.2288 | (1.05) |
Drug cytotoxicity was evaluated by MTT assay as described in Materials and Methods. Data are presented as means±SD (μM) from at least three independent experiments performed in triplicate. The fold reversal of MDR (values given in parentheses) was calculated by dividing the IC50 for cells with the anticancer drugs in the absence of inhibitor by that obtained in the presence of inhibitor.
**
P<0.01, significantly different from those obtained in the absence of inhibitor.